Finepoint Capital LP Lowers Holdings in Ascendis Pharma A/S (NASDAQ:ASND)

Finepoint Capital LP reduced its position in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 2.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 184,872 shares of the biotechnology company’s stock after selling 5,200 shares during the period. Ascendis Pharma A/S comprises about 1.6% of Finepoint Capital LP’s investment portfolio, making the stock its 7th biggest position. Finepoint Capital LP’s holdings in Ascendis Pharma A/S were worth $25,451,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Trexquant Investment LP boosted its holdings in shares of Ascendis Pharma A/S by 235.9% in the 4th quarter. Trexquant Investment LP now owns 27,067 shares of the biotechnology company’s stock worth $3,726,000 after acquiring an additional 19,010 shares in the last quarter. Geode Capital Management LLC boosted its stake in Ascendis Pharma A/S by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 57,077 shares of the biotechnology company’s stock worth $7,858,000 after purchasing an additional 629 shares in the last quarter. Schroder Investment Management Group grew its holdings in shares of Ascendis Pharma A/S by 14.5% during the fourth quarter. Schroder Investment Management Group now owns 92,728 shares of the biotechnology company’s stock worth $12,656,000 after purchasing an additional 11,739 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its stake in shares of Ascendis Pharma A/S by 13.9% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 20,506 shares of the biotechnology company’s stock valued at $2,823,000 after buying an additional 2,506 shares in the last quarter. Finally, New Age Alpha Advisors LLC bought a new position in shares of Ascendis Pharma A/S in the fourth quarter valued at about $507,000.

Ascendis Pharma A/S Stock Performance

ASND opened at $142.67 on Friday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $169.37. The firm has a market cap of $8.66 billion, a PE ratio of -20.09 and a beta of 0.61. The firm’s fifty day moving average is $146.39 and its two-hundred day moving average is $138.01.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.64. Equities analysts forecast that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on ASND. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an “outperform” rating in a research report on Tuesday, February 18th. The Goldman Sachs Group boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. JPMorgan Chase & Co. increased their price objective on Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, March 18th. Morgan Stanley set a $180.00 target price on Ascendis Pharma A/S in a research report on Tuesday, February 18th. Finally, UBS Group assumed coverage on Ascendis Pharma A/S in a report on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $204.64.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.